Abstract | OBJECTIVE: DATA SOURCES: STUDY SELECTION AND DATA EXTRACTION: All English-language articles identified from the data sources were reviewed. DATA SYNTHESIS: CONCLUSIONS: Small trials indicate tetrabenazine may be effective for the treatment of tardive dyskinesia. However, larger, well-conducted trials are needed to confirm these findings. Currently, there is a lack of data coupled with the risk of significant adverse effects to recommend the routine use of tetrabenazine in the management of tardive dyskinesia. Before using tetrabenazine for the management of tardive dyskinesia, all other options should be exhausted and careful monitoring employed.
|
Authors | Jonathan G Leung, Ericka L Breden |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 45
Issue 4
Pg. 525-31
(Apr 2011)
ISSN: 1542-6270 [Electronic] United States |
PMID | 21487088
(Publication Type: Case Reports, Journal Article, Review)
|
Chemical References |
- Adrenergic Uptake Inhibitors
- Tetrabenazine
|
Topics |
- Adrenergic Uptake Inhibitors
(adverse effects, economics, therapeutic use)
- Clinical Trials as Topic
- Humans
- Movement Disorders
(drug therapy)
- Prospective Studies
- Tetrabenazine
(adverse effects, economics, therapeutic use)
|